AKAP‐4: a novel cancer testis antigen for multiple myeloma

Chiriva‐Internati, Maurizio; Ferrari, Raffaele; Yu, Yuefei; Hamrick, Cody; Gagliano, Nicoletta; Grizzi, Fabio; Frezza, Eldo E.; Jenkins, Marjorie; Hardwick, Fred; D’Cunha, Nicholas; Kast, W. Martin; Cobos, Everardo

doi:10.1111/j.1365-2141.2007.06940.x

Cited by 44 publications

(45 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 None of the previous studies have reported humoral response against AKAP4 in CRC patients. Earlier, other investigations have shown humoral response against AKAP4 in small sample size patients, [6 of 19 (32%) in multiple myeloma, 15 10 of 15 (66%) in prostate cancer, 16 and 4 of 17 (23%) in NSCLC. 17 Thus, the present study has put forth an evidence that AKAP4 is highly immunogenic and generates immune response.…”

Section: Discussionmentioning

confidence: 99%

“…14 Moreover, other laboratories have also confirmed AKAP4 protein expression in 65% prostate cancer patients, 16 25% NSCLC patients, 17 and 42% multiple myeloma patients. 15 Thus, AKAP4 expression in CRC patients may be a potential target molecule for immunotherapy. AKAP4 gene expression in various stages, grades and histotypes of CRC patients was found in majority (84%) of the CRC patients (Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…AKAP4, a new member of CT antigen protein family, is expressed exclusively in male germ cells during spermatogenesis. 11 However, AKAP4 expression has also been demonstrated in various malignancies such as breast cancer, 12 epithelial ovarian cancer (EOC), 13 cervix cancer, 14 multiple myeloma, 15 prostate cancer, 16 and non-small cell lung carcinoma (NSCLC). 17 Owing to its expression in cancerous tissues and its potent immunogenicity, AKAP4 is considered as a promising biomarker and immunotherapeutic candidate.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer

et al. 2016

View full text Add to dashboard Cite

Colorectal cancer (CRC) is mainly a disease of developed countries and a major cause of death worldwide. The present study was undertaken to investigate the association of novel cancer testis (CT) antigen, Akinase anchor protein (AKAP4) with CRC. AKAP4 gene and protein was examined by RT-PCR, in situ hybridization and immunohistochemistry (IHC) in 200 clinical specimens of different stages and grades. In addition, humoral response against AKAP4 was detected by enzyme-linked immunosorbent assay and Western blotting in 172 available sera samples of CRC patients. We observed that majority of CRC patients demonstrated AKAP4 expression and elicited immune response. AKAP4 protein expression, based on immunoreactivity score (IRS) predicted presence of CRC with 84% sensitivity, 100% specificity, 100% of positive predictive value (PPV) and 83.33% negative predictive value (NPV). Humoral response against AKAP4 protein was generated in 82% of the CRC patients. Further, statistical analysis revealed that antibodies found against AKAP4 in CRC patients predicted presence of malignancy with 81.98% sensitivity, 100% specificity, 100% PPV, and 63.53% NPV. Collectively, our data suggests that the majority of CRC cases show significant difference of AKAP4 expression among stages and grades and also generated antibodies against AKAP4 protein. Therefore, AKAP4 may be potential candidate molecule for developing as a biomarker for early diagnosis and immunotherapy of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…AKAP4 is currently analyzed as a potential target for cervical cancer immunotherapy [139,140]. The strong expression of AKAP4 in multiple myeloma led to its classification as cancer testes antigen [137].…”

Section: Akaps In Cancermentioning

confidence: 99%

“…AKAP4 is aberrantly expressed in various malignant tissues [137]. Its expression triggers humoral immune responses in ovarian cancer and is associated with malignant properties of cervical, breast and prostate cancer [138].…”

Section: Akaps In Cancermentioning

confidence: 99%

Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease

Deák¹,

Klussmann

2016

CDT

View full text Add to dashboard Cite

A--kinase anchoring proteins (AKAPs) control the localization of cAMP--dependent protein kinase A (PKA) by tethering PKA to distinct cellular compartments. Through additional direct protein--protein interactions with PKA substrates and other signaling molecules they form multi--protein complexes. Thereby, AKAPs regulate the access of PKA to its substrates in a temporal and spatial manner as well as the local crosstalk of cAMP/PKA with other signaling pathways.Due to the increasing information on their molecular functioning and three--dimensional structures, and their emerging roles in the development of diseases, AKAPs move into the focus as potential drug targets. In particular, targeting AKAP--dependent protein--protein interactions for interference with local signal processing inside cells potentially allows for the development of therapeutics with high selectivity and fewer side effects.4

show abstract